Pinterest Stock Surges After Strong Q1 2026 Earnings Beat Expectations 
Samsung Appoints New TV Business Head Amid Rising Competition from Chinese Rivals 
Volvo Car Sales Drop 10% in Early 2026 Despite Growth in Electric Vehicles 
Meta Plans $13B AI Data Center Financing in Texas Amid Surging Big Tech Investment 
Palantir Reports Record Growth, Raises 2026 Revenue Outlook Above Expectations 
NAB First-Half Earnings Miss Forecasts Amid Rising Global Risks 
Continental AG Shares Jump After Q1 Profit Beats Expectations 
AMD Q1 Earnings Surge on AI Demand, Stock Jumps After Strong Guidance 
Philips Reaffirms 2026 Outlook After Strong Q1 Sales and Margin Beat 
Strategy Reports Q1 Loss as Bitcoin Holdings Trigger $14.46 Billion Unrealized Hit 
Strategy Hints at Bitcoin Sales to Cover Dividends After Massive Q1 Loss 
Anthropic Secures $1.5B AI Venture Backed by Wall Street Giants, Shaking Software Sector 
BHP Attracts AI-Focused Investors as Copper Demand Surges 
BMW Keeps 2026 Outlook Despite 25% Profit Drop Amid Tariff Pressure 
Regis Resources and Vault Minerals to Merge in $10.7B Gold Deal 
GameStop Proposes $56 Billion eBay Acquisition in Bold Strategic Move 
Rivian Hints at New R2 Variants as Production Ramps Up Ahead of 2027 Launch 
BOSTON, May 07, 2018 -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on bringing innovative medicines to people with kidney disease, today announced that it will host a conference call and webcast on Thursday, May 10, 2018 at 8:00 a.m. ET to discuss its first quarter 2018 financial results and provide a business update.
To participate in the conference call, please dial (888) 584-2172, (774) 264-7578 (international) and refer to conference ID: 4076397. The call will be webcast live with slides and accessible through the Investors section of the company’s website at www.keryx.com for a period of 15 days after the call.
Keryx Biopharmaceuticals will announce its financial results for this period in a press release to be issued prior to the call.
About Keryx Biopharmaceuticals, Inc.
Keryx Biopharmaceuticals, Inc., with headquarters in Boston, Massachusetts, is focused on the development and commercialization of innovative medicines that provide unique and meaningful advantages to people with kidney disease. The Keryx team consists of approximately 200 committed people working with passion to advance the care of people with this complex disease. This dedication has resulted in two FDA-approved indications for Keryx’s first medicine. For more information about Keryx, please visit www.keryx.com.
Keryx Biopharmaceuticals Contact:
Amy Sullivan
SVP, Corporate Affairs
T: 617-466-3519
[email protected]
